Repurposing Available Drugs to Treat Fragile X Syndrome – FRAXA Initiatives

FRAXA has focused on identifying existing, approved drugs that could be repurposed for Fragile X, allowing potential treatments to move faster and at lower risk than starting from scratch. We’ve worked to advance the most promising candidates toward real-world use.

Read More »
Yue Feng, PhD

Functional Interplay Between FMRP and CDK5 Signaling

FRAXA-funded work showed CDK5 signaling is disrupted in Fragile X. CDK5 drugs are in development for Alzheimer’s so this pathway offers a promising new FX treatment angle.

Read More »

FMRP-MAP1b RNA Interactions in Fragile X Syndrome

FRAXA-funded research by Dr. Mihaela Mihailescu at Duquesne University revealed insights into FMRP and RNA structure in Fragile X. Results were published.

Read More »
Jay Brenman, PhD, at University of North Carolina, FRAXA research grant

Dendritic Spine Formation and Fragile X

With $35K from FRAXA, Dr. Jay Brenman at UNC used fruit fly models to study Fragile X and uncover key disease mechanisms.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)